Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Ovarian Neoplasms 32Breast Neoplasms 25Fallopian Tube Neoplasms 21Multiple Myeloma 18Carcinoma, Ovarian Epithelial 14Lymphoma 8Triple Negative Breast Neoplasms 4Recurrence 3Neoplasms, Plasma Cell 3Hodgkin Disease 3Prostatic Neoplasms 2Neoplasms 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Large B-Cell, Diffuse 2Leukemia 2Hematologic Neoplasms 2Burkitt Lymphoma 2Subcutaneous panniculitis-like T-cell lymphoma 1Solid Tumors 1Sarcoma, Synovial 1Sarcoma, Kaposi 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Peritoneal Neoplasms 1Patient Participation 1Pancreatic Neoplasms 1Osteosarcoma 1Neurofibrosarcoma 1

Interventions

Rituximab 40Cyclophosphamide 29Etoposide 15Doxorubicin 14Vincristine 13Prednisone 13ibrutinib 10fludarabine 10fludarabine phosphate 8Cytarabine 8Mycophenolic Acid 7Bortezomib 7Lenalidomide 6Carmustine 6pembrolizumab 5Peripheral Blood Stem Cell Transplantation 5Melphalan 5Inotuzumab Ozogamicin 5Whole-Body Irradiation 4Tacrolimus 4Carboplatin 4CT-P10 4Brentuximab Vedotin 4Antilymphocyte Serum 4tositumomab I-131 3tocilizumab 3tazemetostat 3obinutuzumab 3idelalisib 3etoposide phosphate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lymphoma, B-Cell × liposomal doxorubicin × Clear all
NCT02911142 2025-07-28

Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Active not recruiting
17 enrolled 21 charts
Lymphoid

Lymphoma, B-Cell, Lymphoma, AIDS-Related, Lymphoma, Primary Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡